AOD-9604: evidence, mechanism, and limitations

AOD-9604 is a synthetic peptide based on the C-terminal region of human growth hormone. Rodent studies reported effects on fat metabolism without the same growth-factor or glucose signals associated with the full hormone. A beta-adrenergic pathway has been proposed from animal work.

That mechanism remains a preclinical hypothesis. A pathway observed in a selected animal model does not demonstrate a meaningful effect in humans.

Multiple controlled human studies were conducted, including larger studies in adults with obesity. The development program did not establish a statistically meaningful weight-loss effect versus placebo and was discontinued for lack of efficacy.

A published pooled safety review described tolerability and biochemical findings from the program. It is important to separate that question from efficacy and to note the authors’ disclosed industry ties.

Claims involving cartilage, joints, or broad metabolic benefit are not supported by adequate controlled human outcome trials. A mechanistic rationale or an uncontrolled signal is not a substitute for a relevant clinical comparison.

AOD-9604 is not approved by the U.S. Food and Drug Administration or Health Canada as a treatment. It is listed by the World Anti-Doping Agency among prohibited peptide hormones, growth factors, related substances, and mimetics. Competitive athletes should rely on current anti-doping rules and qualified sport-medicine guidance.